De-risking an in-licensed route: Indivior and Almac's convergent 10-stage, 29.2 kg scale-up of the selective orexin-1 antagonist C4X3256 (rocavorexant), with T3P replacing the acid-chloride endgame.
Read article →
How a second macrocycle turned a 2.5-fold starting point into RMC-0708 — an orally bioavailable, >200-fold KRAS Q61H-selective RAS(ON) tri-complex inhibitor, with the deposited co-crystal to prove it.
Read article →
A medicinal-chemistry dossier on asundexian (SUNHARBO) — the first approved Factor XIa inhibitor: mechanism, the originator CuAAC/Suzuki route and its chiral-pool patent-avoiding alternative, key intermediates, and the OCEANIC-STROKE data.
Read article →
A medicinal-chemistry dossier on giredestrant (WILSERDLY) — the first oral SERD approved with everolimus for ER+/HER2−, ESR1-mutated advanced breast cancer: mechanism, the crystallization-driven Pictet–Spengler manufacturing route, key intermediates, and the evERA data.
Read article →
A structure-guided, brain-penetrant covalent BChE inhibitor for late-stage Alzheimer's: (S)-(+)-14 carbamoylates the catalytic Ser198 (hBChE IC50 30 nM, no AChE activity), is CNS+, and reverses scopolamine-induced cognitive deficits in mice with no cholinergic side effects — with a co-crystal to prove the mechanism.
Read article →
A clever twist on sirtuin inhibition: acyl-lysine peptides branched at the reacting carbon dock perfectly on NAD+ but refuse to turn over. The lead (KK3) hits SIRT2 at 5 nM in vitro / 13 nM in cells, with no covalent intermediate — validated by 1.8 Å ternary co-crystals.
Read article →
Stanford's next-generation ALDH1B1 inhibitor swaps a metabolically labile biaryl for an aryl-cyclohexyl ether bioisostere: IC50 ~10 nM, 10-fold selectivity for 3D colorectal and pancreatic cancer cultures, and markedly better metabolic stability.
Read article →
Why no single inhibitor fixes β-lactamase-mediated AMR — and how triple combination therapy (β-lactam + SBL inhibitor + MBL-targeting agent) bridges the gap. The inhibitor landscape, the serine vs di-zinc mechanisms, and the FDA-approved aztreonam–avibactam (Emblaveo) milestone, with original structures and binding renders.
Read article →
Macrocyclizing flexible bosutinib locks its 3-cyanoquinoline into AZ137 (HIPK4 IC50 11 nM) — a first-in-class selective chemical probe for a dark kinase, delivered without a target crystal structure. With a redrawn macrocyclization route and a CLK3-surrogate binding render.
Read article →
A convergent, urea-based dual IDO1/TDO inhibitor (compound 66) that rescues VS-15's metabolism while keeping a multimodal mechanism — blocking catalysis and the apo-IDO1/SHP-2 signaling axis. With a redrawn synthesis and an apo-IDO1 binding render.
Read article →